🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 26/02/2015 | 119,05 | 120,23 | 116,50 | 119,97 | +0,95% | 3,13% | 1.303.300 |
| 25/02/2015 | 115,44 | 121,50 | 115,43 | 118,84 | +1,64% | 5,26% | 1.651.100 |
| 24/02/2015 | 117,31 | 117,31 | 114,71 | 116,92 | -0,17% | 2,22% | 1.011.000 |
| 23/02/2015 | 118,28 | 119,91 | 116,07 | 117,12 | -1,26% | 3,25% | 1.262.600 |
| 20/02/2015 | 112,55 | 118,79 | 111,78 | 118,61 | +5,93% | 6,23% | 2.466.900 |
| 19/02/2015 | 113,47 | 113,99 | 111,68 | 111,97 | -1,41% | 2,04% | 1.243.800 |
| 18/02/2015 | 112,34 | 113,78 | 111,84 | 113,57 | +0,15% | 1,73% | 960.900 |
| 17/02/2015 | 113,61 | 115,68 | 112,54 | 113,40 | -0,23% | 2,76% | 999.100 |
| 13/02/2015 | 109,99 | 113,85 | 108,00 | 113,66 | +3,68% | 5,32% | 1.689.600 |
| 12/02/2015 | 109,43 | 109,97 | 108,07 | 109,63 | +0,93% | 1,74% | 1.328.800 |
| 11/02/2015 | 108,68 | 110,22 | 107,23 | 108,62 | +0,18% | 2,75% | 990.900 |
| 10/02/2015 | 108,34 | 109,78 | 107,43 | 108,43 | +0,51% | 2,17% | 1.282.300 |
| 09/02/2015 | 108,29 | 109,60 | 107,16 | 107,88 | -0,72% | 2,25% | 1.183.800 |
| 06/02/2015 | 107,12 | 112,87 | 106,80 | 108,66 | -2,63% | 5,67% | 1.718.700 |
| 05/02/2015 | 109,42 | 111,86 | 108,27 | 111,59 | +2,12% | 3,28% | 1.099.200 |
| 04/02/2015 | 107,50 | 110,64 | 103,75 | 109,27 | +0,51% | 6,41% | 2.302.600 |
| 03/02/2015 | 111,18 | 111,66 | 106,62 | 108,72 | -2,21% | 4,53% | 2.205.100 |
| 02/02/2015 | 110,31 | 111,36 | 107,08 | 111,18 | +0,94% | 3,88% | 1.797.600 |
| 30/01/2015 | 113,17 | 116,19 | 110,00 | 110,14 | -3,50% | 5,47% | 3.027.800 |
| 29/01/2015 | 112,40 | 115,94 | 111,28 | 114,14 | -5,87% | 4,15% | 4.027.000 |
| 28/01/2015 | 124,76 | 124,99 | 120,88 | 121,26 | -1,95% | 3,29% | 1.830.600 |
| 27/01/2015 | 123,91 | 126,54 | 123,51 | 123,67 | -1,16% | 2,45% | 1.103.800 |
| 26/01/2015 | 125,86 | 126,83 | 124,44 | 125,12 | -0,36% | 1,90% | 1.203.800 |
| 23/01/2015 | 126,72 | 127,02 | 125,02 | 125,57 | -1,36% | 1,58% | 973.000 |
| 22/01/2015 | 125,41 | 127,69 | 122,01 | 127,30 | +1,77% | 4,53% | 1.579.300 |
| 21/01/2015 | 123,71 | 126,21 | 123,71 | 125,09 | +0,28% | 2,02% | 1.196.800 |
| 20/01/2015 | 123,14 | 125,26 | 121,03 | 124,74 | +1,53% | 3,44% | 1.096.100 |
| 16/01/2015 | 117,40 | 123,08 | 117,15 | 122,86 | +4,31% | 5,05% | 1.424.700 |
| 15/01/2015 | 120,78 | 121,39 | 117,68 | 117,78 | -2,16% | 3,07% | 1.050.200 |
| 14/01/2015 | 118,42 | 121,22 | 118,42 | 120,38 | -0,18% | 2,36% | 1.224.900 |